Skip to main content
Addgene

pLentiCRISPR-v1-sgTK2_4
(Plasmid #217431)

Print

Ordering

This material is available to academics and nonprofits only.
Item Catalog # Description Quantity Price (USD)
Plasmid 217431 Standard format: Plasmid sent in bacteria as agar stab 1 $85
Add to Cart

Backbone

  • Vector backbone
    pLentiCRISPR v1
  • Vector type
    Mammalian Expression, Lentiviral, CRISPR
  • Selectable markers
    Puromycin

Growth in Bacteria

  • Bacterial Resistance(s)
    Ampicillin, 100 μg/mL
  • Growth Temperature
    37°C
  • Growth Strain(s)
    NEB Stable
  • Copy number
    High Copy

Gene/Insert

  • Gene/Insert name
    sgRNA 4 targeting TK2
  • gRNA/shRNA sequence
    AAGTCTCAGGATTGGTCCGA
  • Species
    H. sapiens (human)
  • Entrez Gene
    TK2 (a.k.a. MTDPS2, MTTK, PEOB3, SCA31, TK2-EXT)
  • Promoter U6

Cloning Information

  • Cloning method Restriction Enzyme
  • 5′ cloning site BsmBI (destroyed during cloning)
  • 3′ cloning site BsmBI (destroyed during cloning)
  • 5′ sequencing primer GTTTTAAAATGGACTATCATATGCTTACCG
    • (Common Sequencing Primers)

Terms and Licenses

  • Academic/Nonprofit Terms
  • Industry Terms
    • Not Available to Industry
Trademarks:
  • Zeocin® is an InvivoGen trademark.

Depositor Comments

Please visit https://doi.org/10.1101/2023.06.04.543621 for bioRxiv preprint.

How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    pLentiCRISPR-v1-sgTK2_4 was a gift from Jason Cantor (Addgene plasmid # 217431 ; http://n2t.net/addgene:217431 ; RRID:Addgene_217431)

  • For your References section:

    Conditional lethality profiling reveals anticancer mechanisms of action and drug-nutrient interactions. Flickinger KM, Wilson KM, Rossiter NJ, Hunger AL, Vishwasrao PV, Lee TD, Mellado Fritz CA, Richards RM, Hall MD, Cantor JR. Sci Adv. 2024 Oct 4;10(40):eadq3591. doi: 10.1126/sciadv.adq3591. Epub 2024 Oct 4. 10.1126/sciadv.adq3591 PubMed 39365851
Related items: